These are top 10 stocks traded on the Robinhood UK platform in July
Jonathan Siegal, Principal Accounting Officer at Vericel Corp (NASDAQ:VCEL), recently sold 1,137 shares of the company’s common stock. The shares were sold on February 25, 2025, at an average price of $52.07 per share, amounting to a total transaction value of $59,203. The transaction comes as Vericel, currently valued at $2.6 billion, trades at a significant premium with a P/E ratio of 725x. According to InvestingPro analysis, the stock appears overvalued at current levels.
Additionally, on February 24, Siegal acquired 1,875 shares of common stock following the vesting of Restricted Stock Units (RSUs). These shares were acquired without any direct purchase cost. However, 738 shares were withheld by Vericel to cover tax obligations related to the RSU vesting, at a price of $52.33 per share, totaling $38,619. The stock has shown significant volatility, with a beta of 1.73, and has declined 9.1% over the past week. Notably, the company is set to report earnings on February 27, 2025.
These transactions were part of an automatic sale plan under a Rule 10b5-1 trading plan, which Siegal adopted on March 13, 2024. Following these transactions, Siegal holds 1,206 shares of Vericel common stock. For comprehensive insider trading analysis and 12 additional key insights about VCEL, visit InvestingPro.
In other recent news, Vericel Corporation reported preliminary fourth-quarter 2024 revenue figures ranging between $75.2 million and $75.7 million, which did not meet the consensus estimate of $77.9 million. Despite this shortfall, the company’s MACI product generated revenue between $68.2 million and $68.7 million, showing substantial growth from the previous quarter and year. Canaccord Genuity and Truist Securities both reaffirmed their Buy ratings on Vericel, with Canaccord increasing its price target to $67 and Truist raising it to $67 as well, reflecting confidence in the company’s growth prospects.
Vericel’s burn franchise, including Epicel and NexoBrid, reported approximately $7 million in revenue for the quarter, with Epicel contributing $6 million. Analysts from H.C. Wainwright highlighted the company’s expansion plans, particularly for MACI Arthro, which is expected to generate significant revenue in 2025. The company plans to submit an Investigational New Drug application for MACI Ankle in 2025 and begin a pivotal Phase 3 study later in the year.
For the full year of 2024, Vericel anticipates revenue between $237.0 million and $237.5 million, slightly below Canaccord’s and consensus estimates. Looking forward to 2025, Vericel projects total revenue growth of 20-23%, with anticipated revenues of up to $292.1 million. The company’s strategic focus on growth and profitability, along with its recent developments, has led analysts to maintain a positive outlook on its financial trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.